Page 1 of 1
Laboratory request no. 1479269
Collected : 04/08/2021 11:26
Received : 04/08/2021 13:52
Reported : 04/08/2021 15:39
Print date: 04/08/2021 15:39
The results will be interpreted in a clinical context by the attending physician
Ordering Physician
Client Information
Contact : Dr Seth Rankin
Job title : General
Practiotioner Company :
London Medical
Laboratory Address : 2
Pensbury Street SW8 4TJ
Surname : Nicolae
Forename(s) : Diaconu
Gender : Male
Date of Birth : 14/12/1990
ID : 059641447
SARS-CoV-2 IgG-AB (S1) I.S. (ELISA)
SARS-CoV-2 IgG-AB (S1) I.S. (ELISA)
Phone : +44 (0) 7873 494300
Results
Unit
Reference Range
0.2
0.4
Ratio
Ratio
< 0.8
< 0.4
The Abbott chemiluminescent microparticle immunoassay SARS-CoV-2 IgG test is designed to detect IgG antibodies to the
nucleocapsid protein of SARS-CoV-2 in serum and plasma from patients that may have been infected by COVID-19.
This test has not been Food and Drug Administration (FDA) cleared or approved and has been authorized by FDA under an
Emergency Use Authorization (EUA). This test has been authorized only for the detection of IgG antibodies against SARSCov-2, not for any other viruses or pathogens.
Current detection of IgA-AB against SARS-COV-2 without simultane- Ous detection of IgG. An isolated IgA result indicates a
recent in- fection. Since a false positive result cannot be excluded (specificity approx. 88 %), we recommend direct detection of
SARS-COV-2 by PCR from the nasopharyngeal swab and a serological follow-up in 2 weeks to confirm seroconversion.